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Small-cell lung cancer (SCLC) accounts for approximately 15% of all cases of lung cancer and is a particularly aggressive form of lung
cancer characterised by a poor prognosis, rapid tumour growth, and early metastasis. Roughly, two-thirds of patients with SCLC
present with extensive disease (ED) and one-third with limited disease (LD). Combination chemotherapy is the most effective
treatment modality for SCLC, and several new agents, including carboplatin, ifosfamide, taxans, and topotecan, have been
demonstrated to be active; however, there are no data on the survival benefit of these drugs. A CPT-11þ cisplatin regimen has
shown improvement in overall survival over the global gold standard regimen, etoposide þ cisplatin (Japanese Clinical Oncology
Group: JCOG 9511), and three confirmatory randomised controlled trials are in progress to determine the reproducibility of the
JCOG 9511 study. JCOG is evaluating the role of CPT-11 and a new triplet regimen containing CPT-11 in limited-stage SCLC.
Strategies and the current protocols of the JCOG are presented and discussed. In the future, it will be essential to evaluate molecular
target-based drugs for LD and ED SCLC with new standard combination chemotherapy regimens that include CPT-11.
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Lung cancer is one of the most common cancers not only in
Western countries but also in Japan as well. Small-cell lung cancer
(SCLC) has a poor prognosis and accounts for approximately 15%
of all lung cancer deaths. It is characterised by an aggressive
clinical course, rapid tumour growth, and metastatic spread, and
despite being a chemo- and radiosensitive tumour, majority of
SCLC patients die because of recurrence after the response to
initial treatment. Roughly, one-third present with limited-stage
disease (LD), and the remainder with extensive-stage disease (ED).
Surgery and radiation therapy have been used as a single modality
or in combined modality therapy but have resulted in few cures
(Hanna and Einhorn 2002). The standard treatment strategy for
LD-SCLC and ED-SCLC is chemoradiotherapy and chemotherapy,
respectively (Evans et al, 1987; Fukuoka et al, 1991; Fukuda et al,
1996; Saijo 2002; Sandler 2002). A cisplatin (CDDP) þ etoposide
(VP-16) (PE) regimen is the most frequently used chemother-
apeutic regimen worldwide, and various strategies, such as the
introduction of new anticancer drugs, non-cross-resistant alter-
native chemotherapy (Evans et al, 1987; Fukuoka et al, 1991;
Murray et al, 2001), weekly dose-intensive chemotherapy (Murray
et al, 1991), high-dose chemotherapy with haematopoietic stem
cell support (Elias et al, 1993), and the evaluation of timing, dose,
or fractionation of radiation therapy have been tested in
randomised controlled trials to improve the results of treatment
of SCLC (Sandler, 2001). Several new anticancer drugs, including
ifosfamide and taxans, have been shown to be active against SCLC,
but, have not resulted in improvement of overall survival. The
most active one of these drugs to date has been the topoisomerase I
inhibitor irinotecan (CPT-11) (Saijo et al, 1994; Le Chevalier et al,
1997; Devore et al, 1998; Kelly, 2001; Shihabi and Belani, 2001).
This review focuses on the contribution of CPT-11 to improvement
of the results of treatment of SCLC and discusses the future
development of CPT-11 in the treatment of SCLC.
SINGLE-AGENT ACTIVITY OF CPT-11 AGAINST SCLC
In the phase I trial of CPT-11, the recommended dose of CPT-11
was determined to be 100–125mgm
 2 once a week and
150mgm
 2 every 2 weeks (Negoro et al, 1991a,b).
A multi-institutional phase II study was conducted in previously
treated and untreated SCLC patients, and nine out of 27 previously
treated patients and four out of 8 previously untreated patients
experienced an objective tumour response (Kanzawa et al, 1990;
Negoro et al, 1991a,b). Masuda used CPT-11 100mg/m
 2 as a 90-
min infusion every week to treat 16 patients with refractory or
relapsed SCLC, and seven out of 15 evaluable patients responded to
CPT-11 (Masuda et al, 1992).
In addition to SCLC, CPT-11 has been demonstrated to be active
as single-agent chemotherapy for non-small-cell-lung-cancer,
colon cancer, breast cancer, uterine cancer, stomach cancer,
ovarian cancer, etc.
DEVELOPMENT OF THE CPT-11þCDDP REGIMEN
It is essential to combine the maximum effective doses of active
anticancer drugs in order to obtain a better therapeutic effect. We
have demonstrated that combinations of cisplatin with topoisome-
rase I inhibitors have an exclusively synergistic effect (Kanzawa et al,
1990; Fukuda et al, 1996). DNA interstrand crosslinks are
significantly increased by such combinations, and DNA repair after
interstrand crosslinks formed by cisplatin is inhibited by topoi-
somerase inhibitors. On the other hand, the topoisomerase I
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www.bjcancer.cominhibitory activities of CPT-11 and SN-38 are increased by CDDP. In
nude mice transplanted with human SCLC, the CPT-11 and CDDP
combination showed a synergistic effect (Tamura et al, 1997). Phase I
studies of CPT-11 and CDDP combinations with or without the
support of granulocyte-colony stimulating factor (G-CSF) were
conducted in untreated patients with stage IV NSCLC. CPT-11 was
given on days 1, 8, and 15, and CDDP on day 1, and the schedule was
repeated every 4 weeks. The dose of CDDP was fixed at 60 or
80mgm
 2. Without the support of G-CSF, the recommended dose of
CPT-11 for a phase II study in combination with 60 and 80mgm
 2
of CDDP was 80 and 60mgm
 2, respectively. The dose-limiting
toxicities were granulocytopenia and diarrhoea (Masuda et al, 1993).
PHASE II STUDY OF CPT-11 AND CDDP
The West Japan Thoracic Oncology Group (WJTOG) conducted a
phase II trial of CPT-11 and CDDP in SCLC. In all 75 untreated
patients with SCLC were treated with 80 or 60mgm
 2 of CPT-11
on days 1, 8, and 15 and 60mgm
 2 of CDDP on day 1 every 28
days. Patients with LD-SCLC received thoracic irradiation after
four cycles of chemotherapy whereas patients with ED received
four or six cycles of chemotherapy. The dose of CPT-11 was
reduced to 60mgm
 2 after four of 10 patients experienced severe
haematological toxicity, diarrhoea, and hepatic toxicity, while one
patient died of toxicity. Among the 35 ED patients, the objective
response rate was 86% (30 patients), with 10 patients (29%) having
a complete response (CR). The median survival time was 13
months. Among the 40 LD patients, 33 (83%) had a response and
12 (30%) had a CR, and the median survival time for this subset of
patients was 14.3% months. The significant grade 3/4 toxicities
were neutropenia (77%), anaemia (39%), nausea (35%), and
diarrhoea (19%) (Kudoh et al, 1998). These results were very
encouraging, especially for ED-SCLC.
PHASE III STUDY OF CPT-11þCDDP VS
VP-16þCDDP (JCOG 9511)
Based on the results of a study of the CPT-11þCDDP combina-
tion, JCOG conducted a phase III study comparing CPT-
11þCDDP with VP-16þCDDP for untreated ED-SCLC.
The study arm consisted of CPT-11 60mgm
 2 on days 1, 8, and
15 and CDDP 60mgm
 2 on day 1, every four weeks, for four
courses. The control arm consisted of VP-16 100mgm
 2 on days
1–3 and CDDP 80mgm
 2 on day 1, every 3 weeks, for four
courses. The initial sample size was 230 patients, 115 cases per
arm, in order to demonstrate a 30% increase in overall survival
with the significant difference of a error Po0.05 and b error o0.8.
However, enrollment into the study was stopped because of a huge
difference (P¼0.00025) in survival on an interim analysis.
In the final data, 154 patients were randomised, 77 into each
arm, and the overall and CR rates were 84 and 3%, respectively, in
the CPT-11þ CDDP arm and 68 and 9%, respectively, in the VP-
16þCDDP arm, (P¼0.02 for the difference in overall response
rate). The median survival time was 12.8 and 9.4 months in the
CPT-11þCDDP arm and VP-16þCDDP arm, respectively. The
CPT-11 þ CDDP arm was characterised by significantly better
survival than the standard regimen, VP-16þ CDDP (P¼0.002
unadjusted one-sided log-rank test). The rates (95% confidence
limit) of overall survival in CPT-11þCDDP arm were 58.4 (47.7–
69.4) % at 1 year and 19.5 (10.0–27.8)% at 2 years: in VP-16 plus
CDDP arm the rates of overall survival at these time points, were
37.7 (26.8–48.5) % and 5.2 (1.0-12.0)%, respectively (Figure 1).
Grade 3/4 leukopenia occurred in 27% of patients on CPT-11 þ
CDDP and in 52% on VP-16 þ CDDP (P¼0.002). Grade 3/4
neutropenia developed in 65% of patients on CPT-11þCDDP and
in 92% on VP-16þCDDP (Po0.001). Grade 3/4 diarrhoea, on the
other hand, occurred in 16% of the patients in the CPT-11þCDDP
arm, but in none of the patients in the VP-16þ CDDP arm
(Po0.001). Treatment with four cycles of CPT-11þ CDDP every 4
weeks yielded a highly significant improvement in survival in ED-
SCLC over standard VP-16þ CDDP, with less myelosuppression.
There were no statistically significant differences between patient
characteristics, and there were slightly more patients with more
favourable pretreatment characteristics, such as female gender, PS
0 or 1, fewer patients with brain metastasis, in the CPT-11þ CDDP
arm. In view of the small sample size in the study, even small
differences in patient characteristics may have resulted in outcome
differences between the two arms. Another problem was com-
pliance with the regimen. Only 29% of patients received the full
dose of chemotherapy without skips or delays in CPT-11þ CDDP
arm. Based on the results of JCOG 9511, CPT-11þ CDDP is
considered the reference chemotherapy arm for ED-SCLC in future
JCOG trials (Noda et al, 2002).
The data of JCOG 9511 are clearly interesting, however, only 154
patients have been randomised. It is essential to evaluate the
reproducibility of the effect of CPT-11. Three randomised
controlled trials, PHA GMA 262, SWOG SO124, and Aventis
GMA 3001, are in progress; to confirm the data obtained in JCOG
9511 (Table 1).
CHEMOTHERAPY WITH CISPLATINþCPT-11þVP-16
The VP-16þCDDP regimen is still considered the standard
regimen in North America, and CPT-11þCDDP showed a survival
benefit in JCOG9511. The combination chemotherapy with CPT-
11þ VP-16 also shows promising results (Karato et al, 1993;
Masuda et al, 1998). It is quite reasonable to investigate the three-
drug combination CPT-11þVP-16þCDDP to increase efficacy
without increasing toxicity (Table 2). The JCOG has conducted two
phase I/II studies of CDDP þ VP-16þCPT-11 combination
chemotherapy using two different schedules: weekly (JCOG 9507)
and four-weekly (JCOG 9512) (Ohe and Saijo, 2002). Based on the
doses determined in the two phase I studies, a randomized phase II
study (JCOG 9902-DI) Table 3 was conducted comparing weekly
and every-four-week schedules of this three-drug combination to
select the appropriate arm for the future phase III trial (JCOG
9902-DI) (Figure 2).
Weekly chemotherapy consisted of CDDP 25mgm
 2 on day 1 of
weeks 1–9, CPT-11 90mgm
 2 on day 1 of weeks 1, 3, 5, 7, and 9,
and VP-16 60mgm
 2 on days 1–3 of weeks 2, 4, 6, and 8, G-CSF
support. Chemotherapy for the every-4-week schedule consists of
CDDP 60mg/m
2 on day 1, CPT-11 60mg/m
2 on days, 1, 8, and 15,
and VP-16 50mgm
 2 on days 1–3, with G-CSF support. The doses
of these agents were decided in phase I studies, but the schedule
Figure 1 Phase III Study of CPT-11/CDD vs VP-16/CDDP in SCLC
(JCOG9511).
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schedule consisted of CDDP 25mgm
 2 on day 1 of weeks 1–9,
escalating doses of CPT-11 on day 1 of weeks 2, 4, 6, and 8, and
VP-16 60mgm
 2 on days 1–3 of weeks 1, 3, 5, 7, and 9, with G-
CSF support. Since we concluded that irinotecan is more active
against SCLC than VP-16 based on the results of JCOG 9511, CPT-
11 and CDDP is given in week 1 instead of VP-16 and CDDP in
JCOG 9902-DI.
A total of 60 patients with chemotherapy-naı ¨ve ED-SCLC have
been enrolled in the study, and the eligibility criteria included age
p70 years, PS 0-2, and no prior therapy. Arm A consisted of P
(25mgm
 2 day 1) weekly for 9 weeks, CPT-11 (90 day 1) in weeks
1, 3, 5, 7 and 9, and VP-16 (60 days 1–3) in weeks 2, 4, 6, and 8.
Arm B consisted of cisplatin (60mgm
 2 day 1), I (60 days 1, 8, 15),
and VP-16 (50 days 1–3) every 4 weeks for four cycles. G-CSF
support was used in both arms. Between August 1999 and October
2000, 60 patients were randomised to arm A (n¼30) and arm B
(n¼30).
Full cycles were delivered in 73 and 70% of the patients in arms
A and B, respectively. The incidences of grade 3–4 neutropenia,
anaemia, thrombocytopenia, infection, and diarrhoea were 57, 43,
27, 7, and 7%, respectively, in arm A, and 87, 47, 10, 13, and 10%,
respectively in arm B. Treatment-related death was observed in
one patient in arm A. The CR rate and partial response (PR) rate
were 7 and 77%, respectively, in arm A, and 17 and 60% in arm B.
MST and the 1-year survival rate were 8.9 months and 40%,
respectively, in arm A, and 12.8 months and 56% in arm B. In
conclusion, arm B was appropriate as an investigational arm in
Table 1 SCLC studies designed to support registration and their current situation
CPT-11+cisplatin small cell-lung cancer studies: study regimens sample size, and survival assumptions
Test regimen Control regimen
Patients Survival
Study CPT-11 Cisplatin Cycles Etoposide Cisplatin Cycles
Test/control
(Accural time) Hazard ratio Status
JCOG
9511
60mgm
 2
D1,8,15
60mgm
 2
D1
Q4weeks 
4 cycles
100mgm
 2
D1–3
80mgm
 2
D1
Q 3weeks 
4 cycles
77/77 1.44 Completed
PHA GMA
262
(North
American study)
65mgm
 2
D1,8
30mgm
 2
D1,8
Q 3 weeks 
X4 cycles
120mgm
 2
D1,3
60mgm
 2
D1
Q3w e e k s
 X4 cycles
200/100
(28 months)
1.33 2:1 randomisation-PS2
pts excluded as
of 1Q02 145 pts accured to date
(sites in US, Canada,
and Australia)
Swog S0124 60mgm
 2
D1,8,15
60mgm
 2
D1
Q 4 weeks 
X4 cycles
100mgm
 2
D1–3
80mgm
 2
D1
Q3w e e k s
 X4 cycles
310/310
(48 months)
1.33 PS2 pts excluded
SWOG kick-off
meeting held 26 April,
2002
Aventis GMA
3001
60mgm
 2
D1,8
80mgm
 2
D1
Q 3 weeks 
X6 cycles
100mgm
 2
D1–3
80mgm
 2
D1
Q3w e e k s
X4 cycles
164/164
(18 months)
1.44 First pt. anticipated in
June 2000.
In all, 13 participating
countries (EU and
Asia Pacific)
Table 3 Randomised phase II (JCOG 9902-DI) study of CDDP, CPT-11,
and VP-16 administered weekly or every 4 weeks for ED-SCLC (August
1999–April 2001)
Arm A
(Weekly)
Arm B
(q 4 weeks)
No of patients 30 30
Median dose intensity
(CDDP/CPT-11/VP-16)
mgm
 2week
 1
21/40/68 15/35/37
Median total dose
(CDDP/CPT-11/VP-16) mgm
 2
225/450/720 240/563/600
CR/PR 2/23 5/18
SD/PD/NE 1/3/1 0/4/3
RR (%) 83 77
Gr toxicity (%)
leucopenia/neutropenia
50/57 53/87
MST (months) 8.9 12.9
1-Year survival (%) 40 56
Table 2 Recent trials of cisplatin/irinotecan/etoposide for SCLC in Japan
Trial Patients Treatment
JCOG9902-DI
(Randomised phase II)
Extensive disease
(n¼30)
Cisplatin 25mgm
 2 day 1
Irinotecan 90mgm
 2 day 1
Etoposide 60mgm
 2 days 1–3
versus Cisplatin 60mgm
 2 day 1
JCOG9903-DI
(pilot study)
Limited disease
(n¼30)
Cycle 1: Cisplatin 80mgm
 2 day 1
Etoposide 100mg/m
 2 1–3
TRT b.i.d. to 45Gy
Multicentre
(Phase II)
Sensitive relapse
(n¼33)
Cisplatin 25mgm
 2 day 1
Refractory (n¼27) Irinotecan 90mgm
 2 day 1
Etoposide 60mgm
 2 days 1–3,
weeks 1,3, 5, 7, 9 weekly
Figure 2 Treatment schema.
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randomised controlled trial comparing a CPT-11þCDDP regimen
consisting of CPT-11 60mgm
 2 on days 1 and 8, and CDDP
60mgm
 2 on day 1 with a CPT-11 þ VP-16 þ CDDP regimen
consisting of CPT-11 60mgm
 2 on days 1 and 8, CDDP 60mgm
 2
on day 1, and VP-16 50mgm
 2 on days 1–3. Both the regimens
will be given every 3 weeks.
TREATMENT OF RECURRENT SCLC WITH A
CPT-11þCDDPþVP-16 REGIMEN
There is no standard treatment for relapsed SCLC (Schulthesis et al,
2001). Since CPT-11 and VP-16 have been studied in several phase
II trials as active agents for relapsed SCLC, we conducted a phase II
study to evaluate the efficacy and toxicity of CPT-11 combined with
weekly CDDP and VP-16 (PE) in patients (pts) with SCLC who had
relapsed at least 8 weeks after completion of first-line therapy.
Patients had to have measurable or assessable disease, be age 75
years old or under, and have performance status of 0 to 2 (ECOG),
and adequate organ function. The PE/CPT regimen consisted of
CDDP 25mgm
 2 on day 1 at 1-week intervals for 9 weeks (at least 6
weeks), VP-16 60mgm
 2 on days 1–3 in weeks 1, 3, 5, 7, and 9 (at
least in weeks 1, 3, 5), and CPT-11 90mgm
 2 in weeks 2, 4, 6, and 8
(at least in weeks 2, 4, 6). After day 1 in week 2, G-CSF was
administered on days when no cytotoxic drugs were given.
Between October 1998 and March 2001, 40 pts were enrolled in
this study. Patient characteristics were median age 67 years (range
41–74), 29 males and 11 females, 5 LD and 35 ED. Prior
chemotherapy included PE in 11 patients, carboplatin and VP-16
in 11, PE/CODE in six, cisplatin and irinotecan in six, PE/CPT in
two, and others in four patients. Eight patients received thoracic
radiotherapy. In all, 32 patients (80%) completed six or more
weeks of chemotherapy. There were five CRs and 26 PRs, and the
overall response rate was 78% (95% CI 64.6–90.4%). The median
survival time was 11.4 months. Grade 3/4 neutropenia and
thrombocytopenia were observed in 73 and 33%, respectively.
Grade 3 nausea/vomiting was observed in 8%, and grade 3/4
diarrohea in 8%. In conclusion, the PE/CPT regimen was active
against relapsed SCLC and well tolerated (Goto et al, 2002).
CPT-11-CONTAINING REGIMENS FOR LD-SCLC
CPT-11-containing regimens are considered to be one of the most
promising strategies for improving the survival of LD-SCLC
patients. Early concurrent thoracic radiation therapy with
combination chemotherapy consisting of VP-16/CDDP is a
standard treatment for LD-SCLC patients (Perry et al 1987; Pignon
et al, 1992; Murray et al, 1993; Jeremic et al, 1997; Work et al,
1997). Twice-daily thoracic radiation therapy and prophylactic
cranial irradiation after a CR have recently been added to the
standard treatment (Trussi et al, 1999; Takada et al, 2002). Thus,
concurrent twice-daily thoracic radiation therapy with combina-
tion chemotherapy consisting of CPT-11/CDDP may be the most
powerful treatment for LD-SCLC patients, if the full dose of CPT-
11 can be given with acceptable toxicity. Previously, the JCOG
conducted a dose-finding study for CPT-11/CDDP plus concurrent
radiation therapy in unresectable stage III NSCLC (JCOG 9405).
The CPT-11 dose intensity in that study was low because of the
need to skip CPT-11 administration of days 8 and/or 15 as a result
of leukopenia or diarrhoea, and the radiation therapy completion
rate was low as well. Based on the results of JCOG 9405,
chemotherapy with CPT-11/CDDP plus concurrent radiation
therapy was deemed unacceptable (Yokoyama et al, 1998).
The JCOG also conducted a phase II study of single-agent CPT-
11 (60mgm
 2) in combination with radiation therapy in NSCLC
(JCOG 9504). When CPT-11 is used as a single agent with
concurrent radiation therapy, the dose of CPT-11 must be reduced
from 100 to 60mgm
 2 in a weekly schedule. However, this dose
reduction may reduce the efficacy of CPT-11 in the treatment of
LD-SCLC patients. Full-dose chemotherapy consisting of VP-16/
CDDP can also be used in combination with concurrent radiation
therapy (Table 3).
Japanese Clinical Oncology Group, therefore, conducted a pilot
study of concurrent twice-daily thoracic radiation therapy plus
VP-16/CDDP followed by three cycles of chemotherapy with
standard doses of CPT-11/CDDP (JCOG-9903-DI). To be eligible,
patients had to have previously untreated LD-SCLC, be o75 years
of age, and have an ECOG performance status (PS) of 0-2 and
adequate organ function. Treatment consisted of 80mgm
 2 of
CDDP on day 1 and 100mgm
 2 of VP-16 on day 1–3. Accelerated
twice daily thoracic radiation therapy (TRT) started on day 2 and
involved administration of 1.5Gy in 30 fractions over a period of 3
weeks. After completion of PE/TRT, the patients received 3 cycles
of CPT-11þCDDP started on day 29. IP consisted of 60mgm
 2 of
CPT-11 on days 1, 8, and 15 and 60mgm
 2 of CDDP on day 1
every 4 weeks.
Between October 1999 and July 2000, 31 patients were enrolled
in the study. Patient characteristics were: male 27, female 4,
median age 62 years, range 43–74 years, PS 0/1: 8/23. Of the 30
patients who received the protocol treatment, 11 pts had a CR, 18
had a PR, and one progressive disease, for a response rate of 97%.
Totally 25 patients received CPT-11þCDDP. Grade 3/4 toxicities
during CPT-11þCDDP phase were: WBC (48/12%), plt (4/0%), Hb
(44/—), diarrohea (4/4%). No treatment-related deaths were
observed. The 1-year survival rate was 79.3% among patients
who received the protocol treatment, and 87.5% among pts who
received the CPT-11þCDDP regimen. The median survival time
has not been obtained (Table 4) (Mori et al, 2002). In conclusion,
PE plus concurrent twice daily TRT followed by three cycles of
Table 4 Phase II (JCOG 9903-DI) study of CDDP and VP-16 plus
concurrent AHTRT followed by three cycles of CPT-11 and CDDP in LD-
SCLC (October 1999–July 2000)
No of patients 31 (male 27, female four)
Delivery of treatment EP/TRT 30
Cycles of IP 1/2/3 24/22/17
(Causes of treatment off: toxicity and patient refusal)
CR/PR 12/17
SD/PD/not treated 0/1/1
RR (%) 94
Toxicity of PE/TRT Grade 4 14/19 (47/63%)
Leukopenia/neutropenia
Toxicity of IP Grade 4 5/5 (21/21%)
Leukopenia/neutropenia
MST/-year survival Not available/79.3%
Figure 3 Randomised phase III trial for LD-SCLC (JCOG 02002):
Ongoing.
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1-year survival rate. JCOG is conducting a phase III study
comparing it with the standard PE concurrent accerelated
hyperfractionated TRT regimen (Figure 3).
CONCLUSIONS
Although dramatic improvements in survival in response to
combination chemotherapy were observed in the 1970s and
1980s, the results of treating SCLC had reached a plateau. Novel
drugs and approaches are essential to further improve the outcome
of treatment. Significant activity of CPT-11 in the treatment of
patients with SCLC provides the first evidence in 20 years that the
survival of SCLC patients can be prolonged, although we must
await the results of confirmatory studies. Current and future trials
of CPT-11 will be aimed at evaluating three-drug regimens
containing CDDP and CPT-11 in multimodality therapies and
targeting limited-stage disease. In addition, CPT-11 may have the
potential to be a part of second-line treatment for SCLC. In the
future, combining a CPT-11 containing regimen with target-based
therapy will also be a major focus of new directions in SCLC
therapy in order to overcome resistance to CPT-11. In Japan,
amrubicin has been demonstrated to be extremely active against
SCLC and the optimal dose for the combination of amrubicin and
CDDP has been decided. The role of amrubicin for the treatment of
SCLC should also be investigated.
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